Description
Denotec 70 mg contains Denosumab, a fully human monoclonal antibody that targets the receptor activator of nuclear factor kappa-B ligand (RANKL). By blocking RANKL, Denosumab prevents the formation and activity of osteoclasts, the cells responsible for bone breakdown.
🔬 Mechanism of Action
Denosumab binds to RANKL and inhibits its interaction with the RANK receptor on osteoclasts. As a result, it:
- Reduces bone resorption
- Increases bone mineral density
- Strengthens bones and lowers fracture risk
This targeted action makes it effective in managing bone-related conditions and complications.
💊 Indications
Denotec 70 mg is indicated for:
- Osteoporosis in postmenopausal women at high risk of fractures
- Osteoporosis in men at high fracture risk
- Bone loss associated with hormone therapy in cancer patients
- Prevention of skeletal-related events in patients with bone metastases from solid tumors
📌 Key Features of Denotec 70 mg
- Strength: 70 mg
- Dosage Form: Subcutaneous injection
- Therapeutic Class: RANKL Inhibitor / Monoclonal Antibody
- Administration: Given as a subcutaneous injection under medical supervision
- Monitoring: Calcium levels and bone health monitoring recommended
⚕️ Benefits of Denosumab
- Reduces risk of fractures
- Improves bone mineral density
- Effective in cancer-related bone complications
- Long-acting therapy with convenient dosing schedule
⚠️ Precautions
- Risk of hypocalcemia; calcium and vitamin D supplementation may be required
- Rare risk of osteonecrosis of the jaw (ONJ)
- Monitor for infections and allergic reactions
- Regular monitoring of calcium levels recommended
- Use under physician supervision
Denotec 70 mg (Denosumab Injection) is an advanced bone-targeted therapy that helps strengthen bones, prevent fractures, and manage skeletal complications in osteoporosis and cancer-related bone disease.
